TNBC lacks the three receptors, or proteins (estrogen, progesterone and Her2), that typically fuel other forms of breast cancer and to which successful treatments are targeted. ???Currently such customized inhibitors have not been developed for TNBC therefore the demand for such therapies is foremost ,??? says Dunn.